Precision Therapeutics, Inc. Presents GeneFx®Colon Signature at the American Society of Colon and Rectal Surgery Symposium (ASCRS), the World's Largest Colorectal Conference

PITTSBURGH--(BUSINESS WIRE)--Precision Therapeutics, a life-science company known for its expertise in the science of personalizing cancer therapy, continues to advance in genomic testing and bioinformatics research. Precision Therapeutics recently added the GeneFx® Colon signature to its array of services to complement Comprehensive Tumor Profiling for stage II colon cancer, and presented data on the test at the American Society of Colon and Rectal Surgery Symposium (ASCRS) June 2-6, 2012 in San Antonio, Texas.